Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - candesartanum cilexetilum, hydrochlorothiazidum - tabletten - candesartanum cilexetilum 16 mg, hydrochlorothiazidum 12,5 mg, excipiens pro compresso. - essenziale ipertonia - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - chlormadinoni acetas, ethinylestradiolum - compresse rivestite con film - chlormadinoni acetas 2 mg, ethinylestradiolum 30 µg, excipiens pro compresso haze. - contraccezione ormonale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - levonorgestrelum, ethinylestradiolum - confetti - levonorgestrelum 150 µg, ethinylestradiolum 30 µg, lactosum monohydricum 52.353 mg, maydis per amylum, povidonum k 25, talco, magnesio stearas, Überzug: povidonum k 90, talco, glycerolum, sintetico 14.187 mg, calcio carbonas, macrogolum 6000, e-171, cera carnauba per compresso haze. - contraccezione ormonale - synthetika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

eg s.p.a. - venlafaxina - venlafaxina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

eg s.p.a. - gliclazide - gliclazide

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

eg s.p.a. - pramipexolo - pramipexolo

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

eg s.p.a. - posaconazolo - posaconazolo

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

eg s.p.a. - tadalafil - tadalafil

Unione Europea - italiano - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agenti antineoplastici - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. per ulteriori informazioni sullo stato del recettore del fattore di crescita epidermico umano 2 (her2), fare riferimento alla sezione 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. per ulteriori informazioni sullo stato her2, fare riferimento alla sezione 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Italia - italiano - Ministero della Salute

tatti non tessuto s,p,a, - teli chirurgici - altri